Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALT-803 and NK cell infusion in refractory/relapsed AML
NCT03050216Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- May 2017
- Primary completion
- Dec 2019
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of nogapendekin alfa inbakicept in acute myeloid leukemia (AML), sponsored by Masonic Cancer Center. Started May 2017; status: completed.
02
Drugs
nogapendekin alfa inbakicept
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03050216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03050216.